{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:16:53Z","timestamp":1794385013650,"version":"4.9.0"},"reference-count":98,"publisher":"BMJ","issue":"11","funder":[{"name":"Society of NeuroInterventional Surgery","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J NeuroIntervent Surg"],"accepted":{"date-parts":[[2023,4,22]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiplatelet and antithrombotic medication management before, during, and after neurointerventional procedures has significant practice variation. This document updates and builds upon the 2014 Society of NeuroInterventional Surgery (SNIS) Guideline \u2018Platelet function inhibitor and platelet function testing in neurointerventional procedures\u2019, providing updates based on the treatment of specific pathologies and for patients with specific comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a structured literature review of studies that have become available since the 2014 SNIS Guideline. We graded the quality of the evidence. Recommendations were arrived at through a consensus conference of the authors, then with additional input from the full SNIS Standards and Guidelines Committee and the SNIS Board of Directors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The management of antiplatelet and antithrombotic agents before, during, and after endovascular neurointerventional procedures continues to evolve. The following recommendations were agreed on. (1) It is reasonable to resume anticoagulation after a neurointerventional procedure or major bleeding episode as soon as the thrombotic risk exceeds the bleeding risk in an individual patient (Class I, Level C-EO). (2) Platelet testing can be useful to guide local practice, and specific approaches to using the numbers demonstrate marked local variability (Class IIa, Level B-NR). (3) For patients without comorbidities undergoing brain aneurysm treatment, there are no additional considerations for medication choice beyond the thrombotic risks of the catheterization procedure and aneurysm treatment devices (Class IIa, Level B-NR). (4) For patients undergoing neurointerventional brain aneurysm treatment who have had cardiac stents placed within the last 6\u201312 months, dual antiplatelet therapy (DAPT) is recommended (Class I, Level B-NR). (5) For patients being evaluated for neurointeventional brain aneurysm treatment who had venous thrombosis more than 3\u2009months prior, discontinuation of oral anticoagulation (OAC) or vitamin K antagonists should be considered as weighed against the risk of delaying aneurysm treatment. For venous thrombosis less than 3\u2009months in the past, delay of the neurointerventional procedure should be considered. If this is not possible, see atrial fibrillation recommendations (Class IIb, Level C-LD). (6) For patients with atrial fibrillation receiving OAC and in need of a neurointerventional procedure, the duration of TAT (triple antiplatelet\/anticoagulation therapy=OAC\u2009plus DAPT) should be kept as short as possible or avoided in favor of OAC plus single antiplatelet therapy (SAPT) based on the individual\u2019s ischemic and bleeding risk profile (Class IIa, Level B-NR). (7) For patients with unruptured brain arteriovenous malformations there is no indication to change antiplatelet or anticoagulant management instituted for management of another disease (Class IIb, Level C-LD). (8) Patients with symptomatic intracranial atherosclerotic disease (ICAD) should continue DAPT following neurointerventional treatment for secondary stroke prevention (Class IIa, Level B-NR). (9) Following neurointerventional treatment for ICAD, DAPT should be continued for at least 3\u2009months. In the absence of new stroke or transient ischemic attack symptoms, reversion to SAPT can be considered based on an individual patient\u2019s risk of hemorrhage versus ischemia (Class IIb, Level C-LD). (10) Patients undergoing carotid artery stenting (CAS) should receive DAPT before and for at least 3 months following their procedure (Class IIa, Level B-R). (11) In patients undergoing CAS during emergent large vessel occlusion ischemic stroke treatment, it may be reasonable to administer a loading dose of intravenous or oral glycoprotein IIb\/IIIa or P2Y12 inhibitor followed by maintenance intravenous infusion or oral dosing to prevent stent thrombosis whether or not the patient has received thrombolytic therapy (Class IIb, C-LD). (12) For patients with cerebral venous sinus thrombosis, anticoagulation with heparin is front-line therapy; endovascular therapy may be considered particularly in cases of clinical deterioration despite medical therapy (Class IIa, Level B-R).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the quality of evidence is lower than for coronary interventions due to a lower number of patients and procedures, neurointerventional antiplatelet and antithrombotic management shares several themes. Prospective and randomized studies are needed to strengthen the data supporting these recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnis-2022-019844","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:22:33Z","timestamp":1684156953000},"page":"1155-1162","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":113,"title":["Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-8781","authenticated-orcid":false,"given":"Clemens M","family":"Schirmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan R","family":"Bulsara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz","family":"Al-Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Haranhalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5885-7259","authenticated-orcid":false,"given":"Steven W","family":"Hetts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"2024052220161379000_15.11.1155.1","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2014-011357"},{"key":"2024052220161379000_15.11.1155.2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25475"},{"key":"2024052220161379000_15.11.1155.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.05.044"},{"key":"2024052220161379000_15.11.1155.4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11239-016-1417-5","article-title":"Evaluation of anticoagulation selection for acute venous thromboembolism","volume":"43","author":"Badreldin","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"2024052220161379000_15.11.1155.5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00228-017-2296-1","article-title":"Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015","volume":"73","author":"Kjerpeseth","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2024052220161379000_15.11.1155.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707278"},{"key":"2024052220161379000_15.11.1155.7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw454"},{"key":"2024052220161379000_15.11.1155.8","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2013-010771"},{"key":"2024052220161379000_15.11.1155.9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431261","article-title":"Neurointerventional stenting and antiplatelet function testing: to do or not to do?","volume":"3","author":"Kass-Hout","year":"2014","journal-title":"Intervent Neurol"},{"key":"2024052220161379000_15.11.1155.10","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A4411"},{"key":"2024052220161379000_15.11.1155.11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaneurol.2015.0654","article-title":"Standard vs modified antiplatelet preparation for preventing thromboembolic events in patients with high on-treatment platelet reactivity undergoing coil embolization for an unruptured intracranial aneurysm: a randomized clinical trial","volume":"72","author":"Hwang","year":"2015","journal-title":"JAMA Neurol"},{"key":"2024052220161379000_15.11.1155.12","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2013-010954"},{"key":"2024052220161379000_15.11.1155.13","doi-asserted-by":"publisher","DOI":"10.3171\/2017.5.JNS162307"},{"key":"2024052220161379000_15.11.1155.14","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyz391"},{"key":"2024052220161379000_15.11.1155.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2005.03.003"},{"key":"2024052220161379000_15.11.1155.16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00415-016-8181-5","article-title":"Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population","volume":"263","author":"Yi","year":"2016","journal-title":"J Neurol"},{"key":"2024052220161379000_15.11.1155.17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/15910199211015042","article-title":"P2Y12 inhibitors for the neurointerventionalist","volume":"28","author":"Borchert","year":"2022","journal-title":"Interv Neuroradiol"},{"key":"2024052220161379000_15.11.1155.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.059"},{"key":"2024052220161379000_15.11.1155.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-512723"},{"key":"2024052220161379000_15.11.1155.20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FPC.0000000000000368","article-title":"International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing","volume":"29","author":"Pereira","year":"2019","journal-title":"Pharmacogenet Genomics"},{"key":"2024052220161379000_15.11.1155.21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/15910199211025917","article-title":"Thromboelastography (TEG) results are predictive of ischemic and hemorrhagic complications in patients with unruptured intracranial aneurysms treated with flow diversion","volume":"28","author":"Javed","year":"2022","journal-title":"Interv Neuroradiol"},{"key":"2024052220161379000_15.11.1155.22","unstructured":"Igor CS , Mernes R , Lobotesis K , et al . Clopidogrel-related platelet inhibition: correlation with peri-operative adverse events in neurointerventional procedures. EJMINT 2014:1437000160."},{"key":"2024052220161379000_15.11.1155.23","first-page":"15910199221122858","article-title":"Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures","volume":"2022","author":"Gegri","year":"2022","journal-title":"Interv Neuroradiol"},{"key":"2024052220161379000_15.11.1155.24","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3405"},{"key":"2024052220161379000_15.11.1155.25","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2012-010582"},{"key":"2024052220161379000_15.11.1155.26","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2019-015091"},{"key":"2024052220161379000_15.11.1155.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024913"},{"key":"2024052220161379000_15.11.1155.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111749"},{"key":"2024052220161379000_15.11.1155.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8662"},{"key":"2024052220161379000_15.11.1155.30","unstructured":"FDA . 2022. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/drug-safety-communications"},{"key":"2024052220161379000_15.11.1155.31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11239-018-1635-0","article-title":"Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection","volume":"45","author":"Vandiver","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"2024052220161379000_15.11.1155.32","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6888"},{"key":"2024052220161379000_15.11.1155.33","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A4365"},{"key":"2024052220161379000_15.11.1155.34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1227\/neu.0000000000002254","article-title":"Comparison of neuroform Atlas stent-assisted coiling and coiling alone in ruptured intracranial aneurysms: a propensity score matching analysis","volume":"92","author":"Yi","year":"2023","journal-title":"Neurosurgery"},{"key":"2024052220161379000_15.11.1155.35","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000374770.09140.FB"},{"key":"2024052220161379000_15.11.1155.36","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2013-010976"},{"key":"2024052220161379000_15.11.1155.37","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0490"},{"key":"2024052220161379000_15.11.1155.38","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2019-014996"},{"key":"2024052220161379000_15.11.1155.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61170-8"},{"key":"2024052220161379000_15.11.1155.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-512681"},{"key":"2024052220161379000_15.11.1155.41","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301"},{"key":"2024052220161379000_15.11.1155.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"2024052220161379000_15.11.1155.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817083"},{"key":"2024052220161379000_15.11.1155.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708454"},{"key":"2024052220161379000_15.11.1155.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.02.050"},{"key":"2024052220161379000_15.11.1155.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611594"},{"key":"2024052220161379000_15.11.1155.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"2024052220161379000_15.11.1155.48","doi-asserted-by":"crossref","first-page":"105654","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105654","article-title":"Risk of stroke vs. intracerebral hemorrhage in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials comparing dual vs. triple antithrombotic therapy","volume":"30","author":"Desai","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2024052220161379000_15.11.1155.49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"suppl_5","key":"2024052220161379000_15.11.1155.50","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1227\/01.NEU.0000237408.95785.64","article-title":"Therapy of brain arteriovenous malformations: multimodality treatment from a balanced standpoint","volume":"59","author":"Richling","year":"2006","journal-title":"Neurosurgery"},{"key":"2024052220161379000_15.11.1155.51","first-page":"9048239","article-title":"Postoperative \"STEMI\u2019\u2019 in intracerebral hemorrhage due to arteriovenous malformation: a case report and review of literature","volume":"2019","author":"Bhanot","year":"2019","journal-title":"Case Rep Crit Care"},{"key":"2024052220161379000_15.11.1155.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2014.07.007"},{"key":"2024052220161379000_15.11.1155.53","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1999.90.4.0695"},{"key":"2024052220161379000_15.11.1155.54","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3171\/jns.2004.100.5.0940","article-title":"Progressive neurological decline after partial spontaneous thrombosis of a Spetzler-Martin grade 5 arteriovenous malformation in a patient with Leiden factor V mutation: management and outcome","volume":"100","author":"Link","year":"2004","journal-title":"J Neurosurg"},{"key":"2024052220161379000_15.11.1155.55","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2011-010098"},{"key":"2024052220161379000_15.11.1155.56","doi-asserted-by":"crossref","DOI":"10.3171\/2017.2.FOCUS1755","article-title":"Novel use of flow diversion for the treatment of aneurysms associated with arteriovenous malformations","volume":"42","author":"Kilburg","year":"2017","journal-title":"Neurosurg Focus"},{"key":"2024052220161379000_15.11.1155.57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000484986","article-title":"Pipeline flex embolization of flow-related aneurysms associated with arteriovenous malformations: a case report","volume":"7","author":"Beaty","year":"2018","journal-title":"Intervent Neurol"},{"key":"2024052220161379000_15.11.1155.58","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.3889\/oamjms.2019.382","article-title":"Surpass flow-diverter in the treatment of two wide-neck aneurysms in the scheme of an arteriovenous malformation patient: a case study","volume":"7","author":"Phuc","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"2024052220161379000_15.11.1155.59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/1591019920954082","article-title":"Endovascular treatment for the flow-related aneurysm originating from an anterior inferior cerebellar artery supplying the cerebellar arteriovenous malformation","volume":"26","author":"Hou","year":"2020","journal-title":"Interv Neuroradiol"},{"key":"2024052220161379000_15.11.1155.60","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201315","article-title":"The clinical dilemma of treating transient ischaemic attack-like symptoms in patients with coexisting arteriovenous malformation","volume":"2014","author":"Jabbari","year":"2014","journal-title":"BMJ Case Rep"},{"key":"2024052220161379000_15.11.1155.61","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11739-018-1918-7","article-title":"Antithrombotic therapy and intracranial bleeding in subjects with sporadic brain arteriovenous malformations: preliminary results from a retrospective study","volume":"13","author":"Sturiale","year":"2018","journal-title":"Intern Emerg Med"},{"key":"2024052220161379000_15.11.1155.62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.25259\/SNI_160_2019","article-title":"Arteriovenous malformation presenting as traumatic subdural hematoma: a case report","volume":"11","author":"Parr","year":"2020","journal-title":"Surg Neurol Int"},{"key":"2024052220161379000_15.11.1155.63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1148\/radiol.2021203487","article-title":"Hereditary hemorrhagic telangiectasia: the convergence of genotype, phenotype, and imaging in modern diagnosis and management of a multisystem disease","volume":"300","author":"Hetts","year":"2021","journal-title":"Radiology"},{"key":"2024052220161379000_15.11.1155.64","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3171\/2016.7.JNS16847","article-title":"Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis","volume":"127","author":"Brinjikji","year":"2017","journal-title":"J Neurosurg"},{"key":"2024052220161379000_15.11.1155.65","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.629865"},{"key":"2024052220161379000_15.11.1155.66","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00277-012-1553-8","article-title":"Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation","volume":"91","author":"Edwards","year":"2012","journal-title":"Ann Hematol"},{"key":"2024052220161379000_15.11.1155.67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMc1213554","article-title":"Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia","volume":"368","author":"Devlin","year":"2013","journal-title":"N Engl J Med"},{"issue":"20 Suppl 2","key":"2024052220161379000_15.11.1155.68","first-page":"S145","article-title":"Intracranial atherosclerotic disease: current concepts in medical and surgical management","volume":"97","author":"Tekle","year":"2021","journal-title":"Neurology"},{"key":"2024052220161379000_15.11.1155.69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043033"},{"key":"2024052220161379000_15.11.1155.70","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001972"},{"key":"2024052220161379000_15.11.1155.71","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2012-010405"},{"key":"2024052220161379000_15.11.1155.72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105335"},{"key":"2024052220161379000_15.11.1155.73","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1693"},{"key":"2024052220161379000_15.11.1155.74","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-9-65","article-title":"VAST: vertebral artery stenting trial. Protocol for a randomised safety and feasibility trial","volume":"9","author":"Compter","year":"2008","journal-title":"Trials"},{"key":"2024052220161379000_15.11.1155.75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fneur.2014.00036","article-title":"The case for angioplasty in patients with symptomatic intracranial atherosclerosis","volume":"5","author":"McTaggart","year":"2014","journal-title":"Front Neurol"},{"key":"2024052220161379000_15.11.1155.76","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A5708"},{"key":"2024052220161379000_15.11.1155.77","first-page":"34","article-title":"A randomized trial comparing primary angioplasty versus stent placement for symptomatic intracranial stenosis","volume":"6","author":"Qureshi","year":"2013","journal-title":"J Vasc Interv Neurol"},{"key":"2024052220161379000_15.11.1155.78","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000257963.65728.e8"},{"key":"2024052220161379000_15.11.1155.79","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.613877"},{"key":"2024052220161379000_15.11.1155.80","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.023996"},{"key":"2024052220161379000_15.11.1155.81","article-title":"Embolic protection devices for carotid artery stenting: a network meta-analysis","volume":"2022","author":"Giannopoulos","year":"2022","journal-title":"Vascular"},{"key":"2024052220161379000_15.11.1155.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2005.01.012"},{"key":"2024052220161379000_15.11.1155.83","doi-asserted-by":"publisher","DOI":"10.1136\/jnis.2011.004762"},{"key":"2024052220161379000_15.11.1155.84","article-title":"Eptifibatide bridging therapy for staged carotid artery stenting and cardiac surgery: safety and feasibility","volume":"2022","author":"Caton","year":"2022","journal-title":"Vascular"},{"key":"2024052220161379000_15.11.1155.85","doi-asserted-by":"crossref","unstructured":"Marnat G , Finistis S , Moreno R , et al . Aspirin versus aggressive antiplatelet therapy for acute carotid stenting plus thrombectomy in tandem occlusions: ETIS registry results. J NeuroIntervent Surg 2022:jnis-2022-019527. doi:10.1136\/jnis-2022-019527","DOI":"10.1136\/jnis-2022-019527"},{"key":"2024052220161379000_15.11.1155.86","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0b013e31820a8364"},{"key":"2024052220161379000_15.11.1155.87","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/STROKEAHA.121.037541","article-title":"Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a multicenter International study","volume":"53","author":"Yaghi","year":"2022","journal-title":"Stroke"},{"key":"2024052220161379000_15.11.1155.88","article-title":"Anticoagulation for cerebral venous sinus thrombosis","volume":"2011","author":"Coutinho","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2024052220161379000_15.11.1155.89","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13381"},{"key":"2024052220161379000_15.11.1155.90","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.007465"},{"key":"2024052220161379000_15.11.1155.91","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2016-012938"},{"key":"2024052220161379000_15.11.1155.92","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2018-013973"},{"key":"2024052220161379000_15.11.1155.93","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamaneurol.2020.1022","article-title":"Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial","volume":"77","author":"Coutinho","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024052220161379000_15.11.1155.94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2106545"},{"key":"2024052220161379000_15.11.1155.95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024052220161379000_15.11.1155.96","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy136"},{"key":"2024052220161379000_15.11.1155.97","unstructured":"Food and Drug Administration . 2011. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/warnings-and-precautions-contraindications-and-boxed-warning-sections-labeling-human-prescription"},{"key":"2024052220161379000_15.11.1155.98","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6814"}],"container-title":["Journal of NeuroInterventional Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnis-2022-019844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T23:25:53Z","timestamp":1716420353000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnis.bmj.com\/lookup\/doi\/10.1136\/jnis-2022-019844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":98,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,10,12]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/jnis-2022-019844"],"URL":"https:\/\/doi.org\/10.1136\/jnis-2022-019844","relation":{},"ISSN":["1759-8478","1759-8486"],"issn-type":[{"value":"1759-8478","type":"print"},{"value":"1759-8486","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]}}}